I Peace, Inc
809 San Antonio Rd
10 articles with I Peace, Inc
I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes
With this high-throughput method, the company has already succeeded in identifying 1,547 HLA-homozygous potential donors and has already generated iPSCs.
I Peace, Inc., a Palo Alto-based biotech start-up, announced that the company had tripled its capacity to manufacture GMP grade iPS cells and iPSC-derived differentiated cells by expanding its facility.
I Peace’s Cell Manufacturing Facility “Peace Engine Kyoto” now registered as U.S. FDA Drug Establishment
The registration recognizes I Peace’s cell manufacturing facility as suitable for drug manufacturing, based on detailed information submitted to the FDA.
Koji Tanabe, Founder and CEO of I Peace, Inc. (https://www.ipeace.com ), has been selected by the judges of World Biz Magazine’s annual awards to be a recipient of the “Top 100 Innovation CEO – 2021” (https://www.worldbizmagazine.net/ ).
Stem Cells for Everyone: I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability
I Peace launched its clinical-grade personalized iPSC banking service in 2020 in Japan and has already banked several individuals’ iPSCs.
I Peace's cell manufacturing facility "Peace Engine Kyoto" receives third-party certification as US cGMP compliant: the facility now meets the standard for both the US and Japanese markets
I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up focusing on Nobel Prize-winning technology "induced pluripotent stem cells (iPSCs)" received a third-party certification as US FDA cGMP compliant for its manufacturing facility “Peace Engine Kyoto,” in Kyoto Japan.
I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic
Avery Therapeutics, a Tucson-based company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, and I Peace, Inc., a Palo Alto-based biotech startup developing, mass-manufacturing, and commercializing Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs)
I Peace, Inc. Obtains IRB Approval for Production of Clinical and Research-Grade iPSCs for Commercial Use
I Peace, Inc., a Palo Alto-based biotech start-up focusing on Nobel Prize-winning induced pluripotent stem cell (iPSC) technology obtains approval from an independent Institutional Review Board (IRB) for the process of generating iPSCs—including donor recruiting, screening, blood draw, iPSC generation, storage, and distribution—for commercial use.
The Alliance for Regenerative Medicine Releases List of Presenting Companies at the 2020 Cell & Gene Meeting on the Mesa
The Alliance for Regenerative Medicine, the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today released the initial slate of presenting companies at its upcoming 2020 Cell & Gene Meeting on the Mesa.
Stem Cells for Everyone: Revolutionizing Regenerative Medicine with Mass Manufacturing of Induced Pluripotent Stem Cells (iPSCs)
I Peace, Inc. (CEO: Koji Tanabe, https://ipeace.com/), a Palo Alto-based biotech startup focusing on Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs) has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-size closed cassette